UnitedHealth Group Inc (NYSE:UNH) – SunTrust Banks issued their Q2 2018 EPS estimates for UnitedHealth Group in a report released on Monday, June 11th. SunTrust Banks analyst D. Macdonald anticipates that the healthcare conglomerate will post earnings per share of $3.03 for the quarter. SunTrust Banks currently has a “Buy” rating and a $300.00 price target on the stock. SunTrust Banks also issued estimates for UnitedHealth Group’s Q3 2018 earnings at $3.32 EPS, Q4 2018 earnings at $3.25 EPS, FY2018 earnings at $12.64 EPS, Q1 2019 earnings at $3.37 EPS, Q2 2019 earnings at $3.50 EPS, Q3 2019 earnings at $3.80 EPS, Q4 2019 earnings at $3.63 EPS and FY2019 earnings at $14.30 EPS.
UNH has been the subject of several other reports. Zacks Investment Research lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Wednesday, March 28th. Credit Suisse Group reissued a “buy” rating on shares of UnitedHealth Group in a report on Friday, March 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $280.00 price objective on shares of UnitedHealth Group in a report on Thursday, March 8th. Morgan Stanley boosted their price objective on UnitedHealth Group from $275.00 to $277.00 and gave the company an “overweight” rating in a report on Wednesday, April 18th. Finally, ValuEngine raised UnitedHealth Group from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Twenty-eight research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $259.28.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.91 by $0.13. The firm had revenue of $55.19 billion during the quarter, compared to analyst estimates of $54.90 billion. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. UnitedHealth Group’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.37 earnings per share.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 26th. Stockholders of record on Monday, June 18th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Friday, June 15th. This is an increase from UnitedHealth Group’s previous quarterly dividend of $0.75. This represents a $3.60 annualized dividend and a dividend yield of 1.41%. UnitedHealth Group’s payout ratio is currently 29.79%.
UnitedHealth Group announced that its board has authorized a share repurchase program on Wednesday, June 6th that permits the company to repurchase 100,000,000 shares. This repurchase authorization permits the healthcare conglomerate to purchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.
In other news, Director Richard T. Burke sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 23rd. The stock was sold at an average price of $234.20, for a total transaction of $3,513,000.00. Following the completion of the transaction, the director now directly owns 1,761,533 shares in the company, valued at $412,551,028.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kenneth Irwin Shine sold 202 shares of the business’s stock in a transaction that occurred on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total value of $47,958.84. Following the transaction, the director now owns 28,948 shares of the company’s stock, valued at $6,872,834.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,202 shares of company stock valued at $9,536,859. Insiders own 0.87% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Exane Derivatives lifted its position in UnitedHealth Group by 15,333.3% in the fourth quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock worth $102,000 after purchasing an additional 460 shares during the period. Aevitas Wealth Management Inc. acquired a new stake in UnitedHealth Group in the fourth quarter worth approximately $102,000. Bamco Inc. NY acquired a new stake in UnitedHealth Group in the first quarter worth approximately $117,000. Pathstone Family Office LLC acquired a new stake in UnitedHealth Group in the fourth quarter worth approximately $129,000. Finally, Trustcore Financial Services LLC acquired a new stake in UnitedHealth Group in the fourth quarter worth approximately $133,000. Institutional investors and hedge funds own 84.99% of the company’s stock.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.